UPenn Researchers Use Xenogen Imaging Tools in Cell-Based Cancer Drug Screen | GenomeWeb

University of Pennsylvania School of Medicine scientists have developed a high-throughput functional cell-based screen using bioluminescence imaging to identify small molecules that modulate p53 transcriptional activity or p53-related proteins in cancer cells, and exhibit anti-cancer activity in human colon cancer xenografts.

The study underscores the importance of p53-related pathways and downstream molecules as potential drug targets, and could help establish bioluminescent cell-based assays as an effective way to screen modulators of such targets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.